



Characterizing Microglia Gene Expression Programs and Regulatory Networks in Neurodegenerative Disease

Victoria Marshe, PhD


Postdoctoral Research Scientist

Center for Translational and Computational Neuroimmunology

Columbia University Irving Medical Centre

Mentor: Philip De Jager, MD PhD

Microglia are CNS-resident macrophages that are highly responsive to their environment



MYELOID-LINEAGE IMMUNE CELLS

Microglia
CNS-resident

yolk-sac derived

Macrophages
peripheral, tissue-resident




Monocytes
circulating

bone-marrow derived


- phagocytosis
- antigen presentation
- cytokine/chemokine signaling

*also dendritic cells



HOMEOSTASIS



Microglia-mediated synapse loss




DISEASE & INJURY




Adapted from Li & Barres. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol* (2018).


Microglial heterogeneity has been captured across disease-associated signatures



Paolicelli et al. *Neuron* (2022).




Keren-Shaul et al. *Cell* (2017).



Hasselmann et al. *Neuron* (2019).

Defining a cross-disease atlas of microglia signatures

Diagnosis	
Alzheimer's Spectrum	
LOAD	35
EOAD	2
MCI	4
ALS Spectrum	
ALS	9
ALS/FTD	2
FTD	1
Parkinsonism Spectrum	
DLBD-PD	5
PSP	3
Other	
TLE	7
MS	2
HD	1
Stroke Lesion	1
DNET	1
Control	1



Banner Sun Health Research Institute (Sun City, AZ)



Brigham and Women's Hospital (Boston, MA)



Massachusetts General Hospital (Boston, MA)



New York Brain Bank (New York, NY)



Rocky Mountain MS Center (Denver, CO)



Rush University Medical Center (Chicago, IL)




UW Medical Center (Seattle, WA)




Dr. John Tuddenham
CTCN, Columbia University

Live microglia show diverse subsets with unique expression signatures



Diagnosis	
Alzheimer's Spectrum	
LOAD	35
EOAD	2
MCI	4
ALS Spectrum	
ALS	9
ALS/FTD	2
FTD	1
Parkinsonism Spectrum	
DLBD-PD	5
PSP	3
Other	
TLE	7
MS	2
HD	1
Stroke Lesion	1
DNET	1
Control	1



Clusters show variable enrichment for the DAM signature



Some cluster shows signatures associated with disease



Clusters show similarity and share transcription signatures




Dr. John Tuddenham
CTCN, Columbia University


Tuddenham. *et al.* A cross-disease human microglial framework identifies disease-enriched subsets and tool compounds for microglial polarization. *bioRxiv* (2022).
 Olah et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease. *Nat Commun*, 2020.

Shifting Towards Understanding The Continuous Nature Of Cellular Expression Programs


Scenario 1



Scenario 2



Scenario 3





	OXPHOS	Glycolysis	Senescence	Inflammation
Cell ₁	●	●	●	●
Cell ₂	●	●	●	●
Cell ₃	●	●	●	●
Cell _N	●	●	●	●


See Cembrowski & Menon. Continuous Variation within Cell Types of the Nervous System. *Trends Neurosci* 2018;41:337–48 for conceptual description.

A High Dimensional Reference Map Of Human T Cell Activation In Highlights The Potential Of Understand Expression Programs

scHPF: single-cell Hierarchical Poisson Factorization



Levitin et al. *Mol Syst Biol* 2019;15:e8557.



Szabo et al. *Nat Commun* 2019;10:4706.



Dr. Peter Sims
Systems Biology
Columbia



Updated live microglia dataset

AD spectrum (97)
(LOAD, EOAD, MCI)
89.5 [47-107] years
248,341 cells

ALS/FTD spectrum (14)
(ALS, FTD, ALS-FTD, ALS-PSP)
62 [33-101] years
52,232 cells


Huntington's disease (4)
62 [33-101] years
11,087 cells

Multiple sclerosis (12)
(PPMS, SPMS)
68 [47-89] years
43,982 cells

PD spectrum (13)
(DLBD, DLBD-PD, MSA, PD, PSP)
80 [70-89] years
30,775 cells

Temporal lobe epilepsy (13)
35 [2-60] years
37,562 cells

Other (8)
(Control, DNET, ET, PART, Stroke)
62 [43-99] years
17,109 cells



Anterior watershed (AWS)
61,277 cells

Frontal cortex (BA9/46)
174,744 cells

Temporal neocortex
37,888 cells

Temporal cortex (BA20/21)
20,610 cells

Motor cortex (BA4)
18,393 cells

Visual cortex (BA17)
1,251 cells

Hippocampus
63,036 cells

Substantia nigra
17,181 cells


Spinal cord
13,103 cells

MS lesion/perilesion
10,625 cells


Thalamus/pulvinar
10,587 cells

Facial nucleus
4,771 cells

Other
(BCN, CB, DN, DNET, OC, STN, BA9 SBWM)
7,622 cells



scHPF: single-cell Hierarchical Poisson Factorization



TISSUES

MODEL

	F1	F2	F3
Cell ₁	1.2	5.6	2.2
Cell ₂	0.3	4.3	3.5
Cell ₃	0.8	2.1	7.8
Cell _N	4	0.3	5.5

CHARACTERIZATION


- Biological enrichment (GO)
- Disease-outcome associations
- External validation

DIAGNOSES




Analysis Overview


BIOLOGICAL CHARACTERIZATION




REGULATORY NETWORK



IN SITU VALIDATION




EVALUATING UTILITY




TAKE AWAYS

- Expression programs are biologically relevant
- Programs show diagnostic specificity, with some distinction between white and grey matter
- Program have shared and unique TF regulation
- The paradigm is broadly applicable across cellular compartments, as well as model systems with and without chemical, genetic, and biological perturbation

Expression programs in microglia across disease and brain regions



Projecting single-nucleus RNAseq data onto the 23-factor single-cell model





Gilad Green,
Hebrew University




Masashi Fujita,
Columbia University

Expression programs show substantial overlap with DEGs for clustering-based microglia subtypes




Significance levels: *FDR-corrected p-value < 0.05.


Expression programs are broadly applicable and capture microglial perturbations associated with disease



NIA-Reagan diagnosis of Alzheimer's disease



● non-AD ● AD



Linear regressions for donor-level expression program scores (mean-aggregated across cells) adjusted for study, age at death, sex, and postmortem interval. For cognitive decline, the model was also adjusted for years of education. *FDR p-value < 0.05

miRoR: Detecting perturbed cell states as differentially abundant graph neighborhoods




ARTICLES

<https://doi.org/10.1038/s41587-021-01033-z>



Differential abundance testing on single-cell data using *k*-nearest neighbor graphs

Emma Dann¹, Neil C. Henderson^{2,3}, Sarah A. Teichmann^{1,4}, Michael D. Morgan^{5,6} and John C. Marioni^{1,5,6}




Assign cells to neighborhoods


nh^1	4	3
nh^2	1	3
nh^3	1	3
nh^4	4	2
nh^5	2	2
nh^6	1	3
\dots	\dots	\dots
nh^i	C_i	\dots

$$C_i \sim NB(\mu_i, \phi_i)$$





Enriched in A
 Enriched in B



Test neighborhoods for differential abundance





AD microglia show a differentially abundant subset of microglia characterized by high DAM2-like (26) expression




Non-AD




AD




Expression programs capture stable patterns across independently-generated datasets



Expression programs capture stable patterns across independently-generated datasets (2)




Identifying a putative factor regulatory network using ARACNe



Lambert et al. The Human Transcription Factors. Cell 172, 650–665 (2018).


Margolin et al. ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context. BMC Bioinformatics 7, S7 (2006).

Microglial expression programs show unique and shared regulons which point toward key processes associated with disease



DAM2-like (26)

IFN response (20)







Spatially-resolved MERFISH shows *in situ* association between *ARID5B* and genes comprising DAM2-like factor 26

TFs validation


- DAM2-like (26)
- ARID5B*
- MITF*
- PPARG*
- CEBPA*

- IFN response (20)
- IRF7*



Continuous expression programs and their regulators in microglia: take-aways

- Identifying discrete subtypes of microglia is challenging
- scHPF factorization is allowing us to define continuous expression programs which show biological and disease-associated relevance
- scHPF recapitulates signals across single-cell and single-nucleus data, human-derived and model systems
- There is a complex network of regulation for expression programs, pointing toward factor-specific and shared regulators
- Spatially-resolved single-cell data provides support for *ARID5B* association with greater expression of DAM2-like factor (26)



IRF7

- Enriched TF motif in antiviral subcluster (Sun et al., Cell, 2023)


ARID5B

- Enriched motif peaks in 'activated' states (Sun et al., Cell, 2023)

MITF

- DAM enriched TF-regulon and ↑ phagocytic activity in iMGLs (Dolan et al., 2024)
- AD-associated subtype upregulates MITF regulon (Lee et al., medRxiv, 2023)

Acknowledgements



Center for Translational and Computational Neuroimmunology (CTCN)

- Dr. Philip De Jager
- Dr. Natacha Comandante-Lou
- Dr. Sinah Engel
- Dr. Verena Haage
- Dr. Masashi Fujita
- Dr. Hans-Ulrich Klein
- Dr. Vilas Menon
- Dr. Marta Olah
- Dr. Mariko Taga
- Dr. John Tuddenham
- Dr. Ya Zhang
- Dr. Lu Zeng

Columbia University

- Dr. Peter Sims
- Dr. Annie Lee

CUIMC MS Center

- Dr. Claire Riley, MD

New York Brain Bank

- Dr. Andrew Teich, MD PhD

Hebrew University

- Dr. Gilad Green
- Dr. Naomi Habib

Banner Sun Health Research Institute (Sun City, AZ)

- Dr. Thomas Beach, MD PhD

Massachusetts General Hospital (Boston, MA)

- Dr. Bradley Hyman, MD PhD
- Dr. Matthew Frosch, MD PhD

NIH NINDS (Bethesda, MD)

- Dr. Daniel Reich, MD PhD

Brigham and Women's Hospital (Boston, MA)

- Dr. Rani Sarkis, MD, MSc
- Dr. Garth Cosgrove, MD
- Dr. Jeffrey Helgager, MD
- Dr. Golden
- Dr. Page Pennell, MD

RUMC/RADC (Chicago, IL)

- Dr. David Bennett, MD
- Dr. Julie Schneider, MD MS

Rocky Mountain MS Center (Denver, CO)

- Dr. John Corboy, MD

University of Washington (Seattle, WA)

- Dr. Dirk Keene


Yale University (New Haven, CT)

- Dr. David Pitt, MD

FUNDING



CIHR IRSC Canadian Institutes of Health Research
Institut de recherche en santé du Canada



NEURODEGENERATION CHALLENGE NETWORK



NIH National Institutes of Health



Biogen